All Vaccine articles – Page 3
-
BusinessUK grants Pfizer–BioNTech Covid-19 vaccine emergency approval
Regulators around the world working towards accelerated decisions on vaccine data
-
-
Business
Oxford–AstraZeneca vaccine joins others with promising interim data
Cheap and fridge-stable candidate at least 60% and up to 90% effective at preventing disease
-
Business
Moderna and Pfizer’s Covid-19 vaccines add more encouraging data
Pfizer–BioNTech reach safety threshold for emergency authorisation, while Moderna’s data peek suggests 95% efficacy
-
News
Ten chemistry innovations that Iupac says could change the world
How chemistry can tackle plastic recycling, climate change and Covid-19 among other challenges
-
Opinion
The ins and outs of vaccine trials
Derek Lowe lays out how the trials work, and why they get paused and restarted
-
Opinion
A promising peep at Covid-19 vaccine efficacy
Pfizer–BioNTech’s will need to be one of many if we are to overcome the pandemic
-
Business
Early indications suggest Pfizer–BioNTech’s Covid-19 vaccine is effective
Company claims 90% efficacy at preventing disease, but experts call for data rather than press releases
-
Opinion
Ethical challenge
Should researchers infect healthy people with Sars-CoV-2 to speed up vaccine testing?
-
News
First Covid-19 challenge study working with live virus planned for the UK
Pending ethics panel approval, healthy volunteers would be infected with Sars-CoV-2 to help understand disease and test vaccines
-
Opinion
Jumping the vaccine queue
Deals between companies and rich governments offset manufacturing risks, but must not compromise supplies to those in need
-
Business
Covid-19 vaccine deals risk skewing supply
International accords including Covax aiming to ensure equitable distribution to poorer countries
-
Business
Protein-based Covid-19 vaccines could overshadow rivals
Although slower to develop, protein-based vaccines are well understood with a strong record of safety and effectiveness
-
News
Rush to approve Covid vaccine prompted by politics may end in disaster
Push by governments to pass a vaccine without appropriate evidence could damage fight against virus
-
Business
Russian Covid-19 vaccine data raises questions
Suspected data manipulation or fabrication casts shadows over safety trial report for hastily-approved Sputnik V
-
Opinion
Facing the challenge of vaccine trials
Russia’s Covid-19 gamble is a stark contrast to even accelerated clinical programmes
-
Business
Russian vaccine launch shocks scientists
Sputnik V to be approved without large human trial data
-
Business
Encouraging signs from initial Covid-19 vaccine trials
Human trials deliver positive immune responses, while primate challenge studies suggest protection is possible
-
Business
What are the risks of fast-tracking a Covid-19 vaccine?
Condensing timelines from years to months inevitably involves compromises
-
Business
Scrambling and gambling to scale up Covid-19 medicines
Organisations work towards making billions of doses of products not yet proven to work
